sunitinib sandoz 12.5 mg gél.
sandoz sa-nv - sunitinib 12,5 mg - gélule - 12,5 mg - sunitinib 12.5 mg - sunitinib
sunitinib sandoz 25 mg gél.
sandoz sa-nv - sunitinib 25 mg - gélule - 25 mg - sunitinib 25 mg - sunitinib
sunitinib sandoz 50 mg gél.
sandoz sa-nv - sunitinib 50 mg - gélule - 50 mg - sunitinib 50 mg - sunitinib
sunitinib viatris 12.5 mg gélules
viatris pharma gmbh - sunitinibum - gélules - sunitinibum 12.5 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika
sunitinib viatris 25 mg gélules
viatris pharma gmbh - sunitinibum - gélules - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika
sunitinib viatris 50 mg gélules
viatris pharma gmbh - sunitinibum - gélules - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agents antinéoplasiques - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib zentiva 12.5 mg gélules
helvepharm ag - sunitinibum - gélules - sunitinibum 12.5 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.20 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (rubrum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika
sunitinib zentiva 25 mg gélules
helvepharm ag - sunitinibum - gélules - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.41 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika
sunitinib zentiva 50 mg gélules
helvepharm ag - sunitinibum - gélules - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium max. 0.81 mg, povidonum k 30, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - cytostatique - synthetika